ELAN vs MRK vs BFLY Stock Comparison

Elanco Animal Health, Merck and Butterfly Network Prices as of Nov 13, 2026 Peers: Industry group
MRK Merck & Co., Inc.
$147.78 +0.3% 1M +59.0% 1Y
Market cap
$357.22B
P/E
145.6x
Revenue (TTM)
$67.38B
Div. yield
0.02%
Pharmaceuticals Healthcare
4 wins
BFLY Butterfly Network, Inc.
$6.09 -19.9% 1M +194.2% 1Y
Market cap
$1.53B
P/E
–
Revenue (TTM)
$123.25M
Div. yield
–
Diagnostic Equipment Healthcare
2 wins

Head to Head

10 decided of 12

Merck leads on 4 of the 12 questions below (Merck 4, Elanco Animal Health 4, Butterfly Network 2). Which ones matter depends on what you are buying for; a cheap multiple and slow growth often come together.

QuestionELANMRKBFLYLeader
Larger companyMarket capitalisation $13.25B $357.22B $1.53B MRK
Cheaper on earningsLower P/E, profitable companies only -90.2x 145.6x -28.5x –
Cheaper on forward earningsLower price / next fiscal year consensus EPS 23.7x 56.6x — ELAN
Faster revenue growthRevenue growth, trailing twelve months +12.1% +4.9% +39.4% BFLY
More profitableNet margin, trailing twelve months -2.9% 3.6% -43.6% MRK
Better return on capitalReturn on invested capital 6.9% 2.5% -30.5% ELAN
Less leveragedLower net debt / EBITDA 2.3x 3.6x 2.3x ELAN
Higher dividend yieldTrailing dividend yield 0.00% 0.02% 0.00% –
Better 1-year returnPrice return, last 12 months +21.8% +59.0% +194.2% BFLY
Better 5-year returnAnnualised price return, 5 years -4.1%/yr +12.0%/yr -6.7%/yr MRK
Less volatileAnnualised volatility, 1 year 43.4% 29.6% 112.2% MRK
Higher overall scoreMean of the five percentile scores vs peers 69/100 61/100 53/100 ELAN

Percentile Scorecard

ELANMRKBFLY

Each axis is the mean percentile of its metrics against the company's industry group. 100 is the best in the group, 50 the middle.

Scores by Axis

AxisELANMRKBFLY
Valuation 92 #52 of 660 85 #97 of 660 31 #167 of 243
Growth 67 #208 of 619 30 #434 of 619 88 #28 of 228
Profitability 85 #90 of 595 90 #59 of 595 39 #137 of 222
Financial Health 31 #473 of 683 21 #538 of 683 68 #81 of 248
Shareholder Returns 73 #126 of 459 79 #98 of 459 41 #94 of 158
Overall 69 61 53
  • ELAN ranked among 695 companies in Pharmaceuticals and Biotechnology
  • MRK ranked among 695 companies in Pharmaceuticals and Biotechnology
  • BFLY ranked among 252 companies in Medical Devices and Diagnostics

Price Performance

Price return, split-adjusted, before dividends. Click a name to hide or show it.

Returns

PeriodELANMRKBFLYSPY
1 month +18.8%+0.3%-19.9% -2.0%
3 months +13.2%+8.8%-31.1% -2.8%
6 months +34.9%+32.7%+59.0% +2.0%
Year to date +18.4%+40.4%+60.3% +10.6%
1 year +21.8%+59.0%+194.2% +12.2%
3 years +136.2%+44.6%+399.2% +68.1%
3 years, per year +33.2%+13.1%+71.0% +18.9%
5 years -18.9%+75.9%-29.2% +61.4%
5 years, per year -4.1%+12.0%-6.7% +10.1%
10 years —+131.1%— +248.5%
10 years, per year —+8.7%— +13.3%

Risk

MeasureELANMRKBFLYSPY
Volatility, 1Y 43.4%29.6%112.2% 13.6%
Downside volatility, 1Y 43.7%24.1%93.8% 13.9%
Beta vs S&P 500, 1Y 1.320.202.99 1.00
Return / volatility, 1Y 0.501.991.73 0.90
Max drawdown, 5Y -75.0%-44.7%-92.2% -25.4%
From 52-week high -0.2%-5.5%-38.7% -3.2%
52-week high $26.84$156.45$9.94 $779.14
52-week low $19.80$92.86$1.97 $631.97

Valuation History

Weekly multiples on trailing twelve-month fundamentals. Negative or extreme readings (a loss year, a collapsed denominator) are left out so the chart stays readable.

MultipleELANMRKBFLY
P/E now vs peer median -91.1xmedian 17.0x 148.7xmedian 17.0x -30.2xmedian 26.5x
P/S now vs peer median 2.6xmedian 8.4x 5.4xmedian 8.4x 13.2xmedian 2.7x
EV/EBITDA now vs peer median 11.8xmedian 14.6x 33.7xmedian 14.6x -29.5xmedian 18.4x
P/FCF now vs peer median 32.8xmedian 19.0x 24.7xmedian 19.0x -58.9xmedian 25.4x
P/B now vs peer median 2.0xmedian 2.0x 8.1xmedian 2.0x 8.8xmedian 2.5x
PEG now vs peer median -1.82median 0.43 -8.16median 0.43 -1.00median 0.98

Financial History

Reported figures by fiscal period, placed on the calendar year (or quarter) each period ended in, so companies with different fiscal years line up.

Trailing twelve monthsELANMRKBFLY
Revenue $5.15B $67.38B $123.25M
Gross profit $2.89B $48.35B $86.60M
Operating income $720.00M $4.76B -$57.83M
Net income -$147.00M $2.45B -$53.69M
Free cash flow $408.00M $14.75B -$27.55M
R&D $381.00M $30.76B $39.57M
EPS (diluted) $-0.29 $0.99 $-0.20
Cash & equivalents $465.00M $9.55B $122.30M
Total debt $3.71B $53.78B $2.92M
Shares (diluted) 506.50M 2.48B 266.50M
Enterprise value $11.29B $320.16B $992.96M

All Metrics

58 metrics · best in bold

Bold marks the best reading: the lowest positive value for multiples, leverage and payout, the highest for everything else. The bar under each value is its percentile against that company's own peers. Hover a value for its rank and the peer median.

Valuation

12 metrics
MetricELANMRKBFLY
P/E -91.1x 148.7x -30.2x
P/FCF 32.8x 24.7x -58.9x
P/Operating cash flow 21.8x 19.5x -69.4x
P/S 2.6x 5.4x 13.2x
P/B 2.0x 8.1x 8.8x
P/Tangible book 3.7x 17.8x 9.1x
EV/EBITDA 11.8x 33.7x -29.5x
EV/EBIT 23.1x 85.8x -26.0x
EV/Revenue 3.2x 6.1x 12.2x
EV/FCF 40.8x 27.7x -54.6x
EV/Operating cash flow 27.1x 21.8x -64.3x
PEG (3Y EPS CAGR) -1.82 -8.16 -1.00

Growth

14 metrics
MetricELANMRKBFLY
Revenue growth (1Y) 12.1% 4.9% 39.4%
Revenue CAGR (3Y) 5.6% 4.3% 21.7%
Gross profit growth (1Y) 14.6% -2.5% 126.4%
Gross profit CAGR (3Y) 4.9% 3.8% 30.5%
Operating income growth (1Y) 20.6% -78.2% 33.5%
Operating income CAGR (3Y) 41.2% -13.9% 26.9%
Net income growth (1Y) -508.3% -87.1% 32.8%
Net income CAGR (3Y) 49.5% -19.1% 24.2%
EPS growth (1Y) -500.5% -87.0% 36.4%
EPS CAGR (3Y) 50.0% -18.2% 30.4%
Operating cash flow growth (1Y) -2.4% 9.6% 5.8%
Operating cash flow CAGR (3Y) 69.1% 2.9% 41.1%
Free cash flow growth (1Y) 10.9% 13.0% -0.1%
Free cash flow CAGR (3Y) 117.8% 3.8% 38.8%

Profitability

14 metrics
MetricELANMRKBFLY
Gross margin 56.2% 71.8% 70.3%
EBITDA margin 27.5% 18.0% -41.4%
Operating margin 14.0% 7.1% -46.9%
Pretax margin -1.8% 7.1% -43.5%
Net margin -2.9% 3.6% -43.6%
FCF margin 7.9% 21.9% -22.4%
Operating cash flow margin 11.9% 27.8% -19.0%
Return on equity -2.2% 5.6% -28.7%
Return on assets -1.1% 1.9% -18.8%
Return on invested capital 6.9% 2.5% -30.5%
Return on capital employed 6.2% 4.6% -26.6%
Asset turnover 0.4x 0.5x 0.4x
Cash conversion (OCF / net income) -4.2x 7.6x 0.4x
Stock comp / revenue 1.5% 1.6% 20.8%

Financial Health

11 metrics
MetricELANMRKBFLY
Debt / assets 27.8% 40.5% 1.0%
Debt / equity 0.6x 1.2x 0.0x
Net debt / EBITDA 2.3x 3.6x 2.3x
Debt / FCF 9.1x 3.6x -0.1x
Liabilities / assets 50.3% 66.1% 36.0%
Equity / assets 49.7% 33.9% 64.0%
Interest coverage 2.8x – -46.8x
Current ratio 2.1x 1.4x 3.6x
Quick ratio 0.9x 0.8x 2.3x
Cash ratio 0.3x 0.3x 1.8x
Altman Z-score 1.72 3.90 5.44

Shareholder Returns

7 metrics
MetricELANMRKBFLY
Dividend yield – 2.3% –
Net buyback yield -0.3% 0.8% -0.5%
Shareholder yield -0.3% 3.1% -0.5%
Payout ratio (earnings) – 341.6% –
Payout ratio (FCF) – 56.7% –
Dividend growth (1Y) – 3.2% –
Dividend CAGR (3Y) – 4.4% –

Analyst Estimates

Solid lines are reported fiscal-year results; dashed lines are the consensus for the years ahead. Hover a year for the analysts' high and low, and how each result compared with its estimate.

ConsensusELANMRKBFLY
Forward P/E 23.7xFY2026 56.6xFY2026 –
EPS, next fiscal year $1.13FY2026 $2.61FY2026 $-0.06FY2026
EPS growth, next FY +20.2%FY2026 -70.9%FY2026 –
EPS growth, the year after +22.1% +228.7% –
Revenue, next fiscal year $4.82BFY2026 $69.66BFY2026 $117.62MFY2026
Revenue growth, next FY +2.4%FY2026 +7.2%FY2026 +20.5%FY2026
Revenue growth, the year after +19.4% -4.6% +22.7%

Institutional Ownership

13F filings, quarter ended Jun 30, 2026
HoldersELANMRKBFLY
Held by institutions 100.0% 79.9% 58.4%
Institutions holding 526 3,804 248
Change in shares held, QoQ +4.4% +2.6% +13.9%
Institutions buying 246 1,844 144
Institutions selling 211 1,469 59
Buyers to sellers 1.17 1.26 2.44

Return Correlation

Daily returns, last 12 months

1.00 means two stocks move in lockstep, 0 that they move independently. Pairs below about 0.5 diversify each other.

ELANMRKBFLY
ELAN 1.00 0.23 0.17
MRK 0.23 1.00 0.02
BFLY 0.17 0.02 1.00

Add a Peer

Largest companies in the same industry

Related Comparisons

Frequently Asked Questions

Which is bigger, ELAN, MRK and BFLY?

Merck (MRK) is the largest by market capitalisation: Elanco Animal Health (ELAN) $13.25B, Merck (MRK) $357.22B, Butterfly Network (BFLY) $1.53B.

Which company is growing faster?

Butterfly Network (BFLY) grew revenue fastest over the trailing twelve months: Elanco Animal Health (ELAN) +12.1%, Merck (MRK) +4.9%, Butterfly Network (BFLY) +39.4%.

Which company is more profitable?

Merck (MRK) has the highest net margin (Elanco Animal Health (ELAN) -2.9%, Merck (MRK) 3.6%, Butterfly Network (BFLY) -43.6%). On return on invested capital, Elanco Animal Health (ELAN) leads (Elanco Animal Health (ELAN) 6.9%, Merck (MRK) 2.5%, Butterfly Network (BFLY) -30.5%).

Which stock has performed better?

Over the past year Butterfly Network (BFLY) returned the most: Elanco Animal Health (ELAN) +21.8%, Merck (MRK) +59.0%, Butterfly Network (BFLY) +194.2%. Over five years, Merck (MRK) compounded fastest (Elanco Animal Health (ELAN) -4.1%/yr, Merck (MRK) +12.0%/yr, Butterfly Network (BFLY) -6.7%/yr). Returns are price only, before dividends.

Which pays a higher dividend?

Only one of these companies pays a dividend: Elanco Animal Health (ELAN) 0.00%, Merck (MRK) 0.02%, Butterfly Network (BFLY) 0.00%. Elanco Animal Health (ELAN) and Butterfly Network (BFLY) pays no regular dividend.

Which stock is riskier?

By one-year price volatility, Merck (MRK) has been the steadiest (Elanco Animal Health (ELAN) 43.4%, Merck (MRK) 29.6%, Butterfly Network (BFLY) 112.2%). Volatility measures how widely the price swings, not the risk of the business.

Which is the better stock, ELAN, MRK and BFLY?

There is no single answer; it depends on what you are buying for. On the 12 head-to-head measures on this page, Merck (MRK) leads on 4. Business Quant does not give investment advice; use the comparison as a starting point for your own research.

Data from SEC filings, exchange prices and consensus estimates, via Business Quant. Percentile scores compare each company with its own peer group, so two companies' scores are each relative to different peers unless you rank against the whole market. Price returns exclude dividends. Nothing on this page is investment advice.